Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy

被引:52
|
作者
Fisher, Jonathan [1 ]
Anderson, John [1 ]
机构
[1] UCL, London, England
来源
FRONTIERS IN IMMUNOLOGY | 2018年 / 9卷
基金
英国惠康基金;
关键词
gamma delta; chimeric antigen receptor; adoptive transfer; alpha beta T cells; cancer immunotherapy; CHIMERIC-ANTIGEN-RECEPTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; MELANOMA-ASSOCIATED ANTIGEN; GENE-THERAPY; ANTITUMOR-ACTIVITY; NK CELLS; ADOPTIVE IMMUNOTHERAPY; NONPEPTIDE ANTIGENS; HUMAN NEUROBLASTOMA; PRESENTING CELLS;
D O I
10.3389/fimmu.2018.01409
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Sharing both innate and adaptive immune properties,gamma delta T cells are attractive candidates for cellular engineering. As the cancer immunotherapy field becomes increasingly busy, orthogonal approaches are required to drive advancement. Engineering of alternative effector cell types such as gamma delta T cells represents one such approach. gamma delta T cells can be modified using many of the techniques used in alpha beta T cell engineering, with the added advantage of innate-like tumor recognition and killing. Progress has been made in T-cell receptor transfer to and from gamma delta T cells as well as in a number of chimeric antigen receptor-based strategies. As the cancer immunotherapy field moves beyond repetitive iteration of established constructs to more creative solutions, gamma delta T cells may offer an attractive chassis to drive anti-tumor responses that are not only broader, but also possess a more favorable safety profile.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Human gamma delta T Cells and Tumor Immunotherapy
    Tanaka, Yoshimasa
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2006, 46 (01) : 11 - 23
  • [2] CRISPR/Cas9-Based Engineering of Gamma-Delta T Cells for Cancer Immunotherapy
    Pomeroy, Emily J.
    Claudio-Vazquez, Patricia N.
    Moriarity, Branden S.
    Webber, Beau R.
    MOLECULAR THERAPY, 2020, 28 (04) : 504 - 505
  • [3] Targeting gamma delta T cells for cancer immunotherapy: bench to bedside
    Gogoi, Dimpu
    Chiplunkar, Shubhada V.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2013, 138 : 755 - 761
  • [4] Immunotherapy With Human Gamma Delta T Cells Synergistic Potential of Epigenetic Drugs?
    Bhat, Jaydeep
    Kouakanou, Leonce
    Peters, Christian
    Yin, Zhinan
    Kabelitz, Dieter
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [5] Human gamma delta T regulatory cells in cancer: fact or fiction?
    Wesch, Daniela
    Peters, Christian
    Siegers, Gabrielle Melanie
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [6] Potential of gamma/delta T cells for solid tumor immunotherapy
    Zhu, Dantong
    Ren, Xijing
    Xie, Wanting
    Chen, Jianjun
    Liang, Shiying
    Jiang, Mingzhe
    Wang, Junyi
    Zheng, Zhendong
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [7] Contemplating Dichotomous Nature of Gamma Delta T Cells for Immunotherapy
    Bhat, Jaydeep
    Placek, Katarzyna
    Faissner, Simon
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] Human gamma delta T cells in tuberculosis
    Poquet, Y
    Halary, F
    Champagne, E
    Davodeau, F
    Gougeon, ML
    Bonneville, M
    Fournie, JJ
    RESEARCH IN IMMUNOLOGY, 1996, 147 (8-9): : 542 - 549
  • [9] Current Approaches to Engineering of NK Cells for Cancer Immunotherapy
    Streltsova, M. A.
    Barsov, E. V.
    Erokhina, S. A.
    Sapozhnikov, A. M.
    Kovalenko, E. I.
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (24) : 2810 - 2824
  • [10] Gamma delta (?d) T cells in cancer immunotherapy; where it comes from, where it will go?
    Deng, Jiechu
    Yin, Hongna
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2022, 919